Liang Xiong, Lei Tang (唐磊), Wenfeng Zhao, Rongtao Wang, Cheng Cheng, Daoping Wang, Yechun Xu, Lei Tang (汤磊), Yanhua Fan
{"title":"在非小细胞肺癌中具有有效抗肿瘤活性的PI5P4Kγ正构-变构双抑制剂","authors":"Liang Xiong, Lei Tang (唐磊), Wenfeng Zhao, Rongtao Wang, Cheng Cheng, Daoping Wang, Yechun Xu, Lei Tang (汤磊), Yanhua Fan","doi":"10.1016/j.jare.2025.09.024","DOIUrl":null,"url":null,"abstract":"<h3>Introduction</h3>Phosphatidylinositol 5-phosphate 4-kinase type II gamma (PI5P4Kγ) has emerged as a promising therapeutic target in oncology due to its key role in cancer progression. However, currently available inhibitors targeting either the orthosteric or allosteric sites of PI5P4Kγ suffer from limited <em>in vitro</em> activity and in vivo validation.<h3>Objectives</h3>This study aimed to develop a highly potent and selective PI5P4Kγ inhibitor capable of simultaneously engaging both the orthosteric and allosteric sites, as well as to validate their potential in therapy for non-small cell lung cancer (NSCLC) were investigated.<h3>Methods</h3>Through the structural modification of the propionamide side chain of the pyridine ring and the N3 substituent of the quinazolinone, the structure–activity relationship (SAR) was elucidated, leading to the identification of the target compound <strong>n40</strong>. The binding mode of <strong>n40</strong> to PI5P4Kγ, was elucidated by X-ray crystallography. <em>In vitro</em> effects were assessed through KINOMEscan Technology, cell proliferation, apoptosis, and EMT analysis. In vivo efficacy was evaluated using an HCC827 xenograft mouse model. Both single-dose (up to 400 mg/kg) and repeated-dose (20–180 mg/kg/day for 28 days) toxicity studies of <strong>n40</strong> were conducted in C57BL/6 mice, with comprehensive monitoring of physiological parameters and organ toxicity indices.<h3>Results</h3>Compound <strong>n40</strong> exhibited a strong binding affinity for PI5P4Kγ (<em>K</em><sub>d</sub> = 6.55 nM), with 3,000-fold selectivity over other two isoforms. Additionally, it displayed sub-50 nM antiproliferative activity in NSCLC cells with higher PI5P4Kγ levels. X-ray crystallography revealed <strong>n40</strong> simultaneously binds to both orthosteric and a novel<!-- --> <!-- -->allosteric pocket. Functionally, <strong>n40</strong> induced S-phase arrest, apoptosis, and EMT reversal and PI3K/AKT signaling inhibition in a PI5P4Kγ-dependent manner. In HCC827 xenografts, <strong>n40</strong> achieved > 60 % tumor growth inhibition without any observed toxicity.<h3>Conclusion</h3>This study establishes PI5P4Kγ as a druggable target in NSCLC and demonstrates that dual orthosteric–allosteric targeting is a viable strategy to achieve potent and selective PI5P4Kγ inhibitors.","PeriodicalId":14952,"journal":{"name":"Journal of Advanced Research","volume":"61 1","pages":""},"PeriodicalIF":13.0000,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Orthosteric–allosteric dual inhibitors of PI5P4Kγ with potent antitumor activity in non-small cell lung cancer\",\"authors\":\"Liang Xiong, Lei Tang (唐磊), Wenfeng Zhao, Rongtao Wang, Cheng Cheng, Daoping Wang, Yechun Xu, Lei Tang (汤磊), Yanhua Fan\",\"doi\":\"10.1016/j.jare.2025.09.024\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<h3>Introduction</h3>Phosphatidylinositol 5-phosphate 4-kinase type II gamma (PI5P4Kγ) has emerged as a promising therapeutic target in oncology due to its key role in cancer progression. However, currently available inhibitors targeting either the orthosteric or allosteric sites of PI5P4Kγ suffer from limited <em>in vitro</em> activity and in vivo validation.<h3>Objectives</h3>This study aimed to develop a highly potent and selective PI5P4Kγ inhibitor capable of simultaneously engaging both the orthosteric and allosteric sites, as well as to validate their potential in therapy for non-small cell lung cancer (NSCLC) were investigated.<h3>Methods</h3>Through the structural modification of the propionamide side chain of the pyridine ring and the N3 substituent of the quinazolinone, the structure–activity relationship (SAR) was elucidated, leading to the identification of the target compound <strong>n40</strong>. The binding mode of <strong>n40</strong> to PI5P4Kγ, was elucidated by X-ray crystallography. <em>In vitro</em> effects were assessed through KINOMEscan Technology, cell proliferation, apoptosis, and EMT analysis. In vivo efficacy was evaluated using an HCC827 xenograft mouse model. Both single-dose (up to 400 mg/kg) and repeated-dose (20–180 mg/kg/day for 28 days) toxicity studies of <strong>n40</strong> were conducted in C57BL/6 mice, with comprehensive monitoring of physiological parameters and organ toxicity indices.<h3>Results</h3>Compound <strong>n40</strong> exhibited a strong binding affinity for PI5P4Kγ (<em>K</em><sub>d</sub> = 6.55 nM), with 3,000-fold selectivity over other two isoforms. Additionally, it displayed sub-50 nM antiproliferative activity in NSCLC cells with higher PI5P4Kγ levels. X-ray crystallography revealed <strong>n40</strong> simultaneously binds to both orthosteric and a novel<!-- --> <!-- -->allosteric pocket. Functionally, <strong>n40</strong> induced S-phase arrest, apoptosis, and EMT reversal and PI3K/AKT signaling inhibition in a PI5P4Kγ-dependent manner. In HCC827 xenografts, <strong>n40</strong> achieved > 60 % tumor growth inhibition without any observed toxicity.<h3>Conclusion</h3>This study establishes PI5P4Kγ as a druggable target in NSCLC and demonstrates that dual orthosteric–allosteric targeting is a viable strategy to achieve potent and selective PI5P4Kγ inhibitors.\",\"PeriodicalId\":14952,\"journal\":{\"name\":\"Journal of Advanced Research\",\"volume\":\"61 1\",\"pages\":\"\"},\"PeriodicalIF\":13.0000,\"publicationDate\":\"2025-09-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Advanced Research\",\"FirstCategoryId\":\"103\",\"ListUrlMain\":\"https://doi.org/10.1016/j.jare.2025.09.024\",\"RegionNum\":1,\"RegionCategory\":\"综合性期刊\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MULTIDISCIPLINARY SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Advanced Research","FirstCategoryId":"103","ListUrlMain":"https://doi.org/10.1016/j.jare.2025.09.024","RegionNum":1,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}
Orthosteric–allosteric dual inhibitors of PI5P4Kγ with potent antitumor activity in non-small cell lung cancer
Introduction
Phosphatidylinositol 5-phosphate 4-kinase type II gamma (PI5P4Kγ) has emerged as a promising therapeutic target in oncology due to its key role in cancer progression. However, currently available inhibitors targeting either the orthosteric or allosteric sites of PI5P4Kγ suffer from limited in vitro activity and in vivo validation.
Objectives
This study aimed to develop a highly potent and selective PI5P4Kγ inhibitor capable of simultaneously engaging both the orthosteric and allosteric sites, as well as to validate their potential in therapy for non-small cell lung cancer (NSCLC) were investigated.
Methods
Through the structural modification of the propionamide side chain of the pyridine ring and the N3 substituent of the quinazolinone, the structure–activity relationship (SAR) was elucidated, leading to the identification of the target compound n40. The binding mode of n40 to PI5P4Kγ, was elucidated by X-ray crystallography. In vitro effects were assessed through KINOMEscan Technology, cell proliferation, apoptosis, and EMT analysis. In vivo efficacy was evaluated using an HCC827 xenograft mouse model. Both single-dose (up to 400 mg/kg) and repeated-dose (20–180 mg/kg/day for 28 days) toxicity studies of n40 were conducted in C57BL/6 mice, with comprehensive monitoring of physiological parameters and organ toxicity indices.
Results
Compound n40 exhibited a strong binding affinity for PI5P4Kγ (Kd = 6.55 nM), with 3,000-fold selectivity over other two isoforms. Additionally, it displayed sub-50 nM antiproliferative activity in NSCLC cells with higher PI5P4Kγ levels. X-ray crystallography revealed n40 simultaneously binds to both orthosteric and a novel allosteric pocket. Functionally, n40 induced S-phase arrest, apoptosis, and EMT reversal and PI3K/AKT signaling inhibition in a PI5P4Kγ-dependent manner. In HCC827 xenografts, n40 achieved > 60 % tumor growth inhibition without any observed toxicity.
Conclusion
This study establishes PI5P4Kγ as a druggable target in NSCLC and demonstrates that dual orthosteric–allosteric targeting is a viable strategy to achieve potent and selective PI5P4Kγ inhibitors.
期刊介绍:
Journal of Advanced Research (J. Adv. Res.) is an applied/natural sciences, peer-reviewed journal that focuses on interdisciplinary research. The journal aims to contribute to applied research and knowledge worldwide through the publication of original and high-quality research articles in the fields of Medicine, Pharmaceutical Sciences, Dentistry, Physical Therapy, Veterinary Medicine, and Basic and Biological Sciences.
The following abstracting and indexing services cover the Journal of Advanced Research: PubMed/Medline, Essential Science Indicators, Web of Science, Scopus, PubMed Central, PubMed, Science Citation Index Expanded, Directory of Open Access Journals (DOAJ), and INSPEC.